-+ 0.00%
-+ 0.00%
-+ 0.00%

CareDx completes acquisition of Naveris

PUBT·07/01/2026 20:05:51
Listen to the news
CareDx completes acquisition of Naveris
  • CareDx completed its acquisition of Naveris, clearing all closing conditions for the deal first disclosed in April 2026.
  • Naveris brings NavDx, a blood test for HPV-driven head and neck and anal cancers, positioned for post-treatment MRD surveillance.
  • NavDx is the only Medicare-covered MRD assay for these HPV-positive cancers, carrying an ADLT Medicare reimbursement rate of USD 1,800.
  • Naveris generated about USD 35 million of revenue in 2025, more than doubling year over year; over 130,000 tests have been reported.
  • Naveris will be consolidated into CareDx financial results starting in Q3 2026; estimated addressable market cited at more than USD 12 billion.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CareDx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607011605BIZWIRE_USPR_____20260701_BW539330) on July 01, 2026, and is solely responsible for the information contained therein.